Covaxin Covid 2023 - Search Videos

Covaxin shows 77.8% efficacy in phase 3 trial data: All you need to know | Covid

Covaxin shows 77.8% efficacy in phase 3 trial data: All you need to know | Covid

Hindustan TimesMohammad Shuaib

COVID-19: Bharat Biotech's Covaxin likely to get WHO nod this week

COVID-19: Bharat Biotech's Covaxin likely to get WHO nod this week

Centre to increase production of Covaxin to address shortage of COVID-19 vaccine

Centre to increase production of Covaxin to address shortage of COVID-19 vaccine

India approves Covishield and Covaxin COVID-19 vaccines: Here are the key things to know

India approves Covishield and Covaxin COVID-19 vaccines: Here are the key things to know

FDA signs off on updated COVID vaccines that target circulating variants

FDA signs off on updated COVID vaccines that target circulating variants

ABC13 HoustonJacqueline Howard,CNN

WHO's emergency use approval to Covaxin delayed till October 5

WHO's emergency use approval to Covaxin delayed till October 5

50 Million Doses Of Covaxin Set To Expire Early 2023 Due To Poor Off Take: Report

50 Million Doses Of Covaxin Set To Expire Early 2023 Due To Poor Off Take: Report

The country's 'first' indigenous COVID-19 vaccine COVAXIN, developed by city-based Bharat Biotech in collaboration with ICMR and NIV, has got the nod for human clinical trials from the Drug Controller General of India, the company said on Monday. The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and immune response, would start across the country next month. | CNBC-TV18

5.4K viewsJun 30, 2020

FacebookCNBC-TV18

COVAXIN phase-3 results show interim efficacy of 81%: Bharat Biotech releases data

WHO nod for Bharat Biotech's Covaxin for EUL expected by October

India TodayIndia Today Television

WHO approves Bharat Biotech's Covaxin

Covaxin effectively neutralises both Alpha, Delta variants of Covid-19: US' top health institute

Covaxin 77.8% effective against Covid: Lancet

India TodayIndia Today Television

'Not scientifically designed': Bharat Biotech rejects study that claimed Covaxin less effective than Covishield

Covaxin likely to get WHO's approval by the end of Sept: Sources

India TodayIndia Today Television

Bharat Biotech submits Covaxin Phase 3 trial data, expert panel meet today

Covaxin's Phase 2/3 trial on children to be completed by September

What to expect with COVID-19 in 2023

COVAXIN Human Trial Latest Update: Country's First Coronavirus Vaccine To Be Launched On August 15

onlymyhealth.com

Covaxin, the homegrown coronavirus vaccine that was authorised for use in January before full clinical trial data, has been declared "safe, immunogenic with no serious side effects" by Lancet that has published its Phase 2 results. Medical journal Lancet has said that efficacy cannot be determined by Phase 2 trials but the vaccine made by Hyderabad-based Bharat Biotech is "safe/immunogenic". The Lancet report says the results reported in the study of Phase 2 results do not permit efficacy assess

27.9K viewsMar 9, 2021

Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing |

Covaxin gets WHO nod, doctors hail global recognition

Developing Covaxin in ‘just 10 months’ was an enormous challenge: Bharat Biotech

Covaxin, the Covid-19 vaccine, being developed by Bharat Biotech is now undergoing phase-3 trials. The company is also working on another vaccine for Covid-19. The new vaccine would be in the form of nasal drops and can be ready by next year. Bharat Biotech is the only vaccine company in the world which has BSL3 production facility. Covaxin is being developed by Bharat Biotech, in collaboration with ICMR and National Institute of Virology. | The Times of India

29.4K viewsNov 16, 2020

FacebookThe Times of India

WHO technical advisory to meet on November 3 for Covaxin approval

Covaxin Phase 3 Data Shows 77.8% Efficacy, Says Lancet

Covaxin's phase 3 results soons, says Bharat Biotech

The Indian Council of Medical Research has revealed that a mix of Covishield and Covaxin, the two main vaccines of India's Covid vaccination programme, can actually yield better results. However, the top medical body added that more detailed and in-depth research must be done on the limitations, as the study is done merely on 18 participants. | NDTV

21.6K viewsAug 9, 2021

No Nod For Covaxin Yet, Final WHO Assessment On November 3

NDTVRishika Baruah

Covaxin Recommended For Next Phase Of Trials For 2-18 Age Group: Report |

See more